<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143711</url>
  </required_header>
  <id_info>
    <org_study_id>DF1001-001</org_study_id>
    <nct_id>NCT04143711</nct_id>
  </id_info>
  <brief_title>Study of DF1001 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dragonfly Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dragonfly Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell&#xD;
      activation signals to specific receptors on cancer cells. The study will occur in two phases.&#xD;
      The first phase will be a dose escalation phase, enrolling patients with various types of&#xD;
      solid tumors that express human epidermal growth factor receptor 2 (HER2). Two combination&#xD;
      therapy cohorts will be opened for enrollment, DF1001 + nivolumab and DF1001 + Nab&#xD;
      paclitaxel. The second phase will include a dose expansion using the best dose selected from&#xD;
      the first phase of the study. Multiple cohorts will be opened with eligible patients having&#xD;
      either selected solid tumors, or solid tumors expressing high levels of HER2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of number of dose limiting toxicities experienced on study as defined per criteria in the study protocol</measure>
    <time_frame>First 3 weeks of treatment for each subject.</time_frame>
    <description>To assess the number of adverse events experienced during the study that meet dose limiting toxicity criteria per the study protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Overall Response Rate</measure>
    <time_frame>Through 90 days after completion of the study, an average of 1 year.</time_frame>
    <description>To assess the Overall Response Rate (ORR) per RECIST version 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of DF1001 will be determined at various time points</measure>
    <time_frame>From start of treatment up through 28 days after last treatment.</time_frame>
    <description>Concentration vs time of DF1001 will be measured using blood samples taken a various time points on study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of DF1001 immunogenicity</measure>
    <time_frame>Every 3 weeks up to 28 days after last treatment.</time_frame>
    <description>Evaluate the immunogenicity of DF1001 by measuring the number of patients developing anti-DF1001 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Best Overall Response</measure>
    <time_frame>Through 90 days after completion of the study, an average of 1 year.</time_frame>
    <description>To assess Best Overall Response (BOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Duration of Response</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>To assess Duration of Response (DOR) of DF1001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Progression Free Survival (PFS)</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>To assess Progression Free Survival (PFS) for DF1001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Overall Survival (OS) time.</measure>
    <time_frame>Time from enrollment in the study until death, measured up to 2 years after last treatment on study.</time_frame>
    <description>To assess Overall Survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess number of adverse events observed during treatment with DF1001 in combination with nivolumab</measure>
    <time_frame>Screening visit up to 28 days after last treatment on study.</time_frame>
    <description>To assess the safety of DF1001 in Combination therapy with nivolumab by measuring Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess number of adverse events observed during treatment with DF1001 in combination with Nab paclitaxel</measure>
    <time_frame>Screening visit up to 28 days after last treatment on study.</time_frame>
    <description>To assess the safety of DF1001 in Combination therapy with Nab paclitaxel by measuring Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Monotherapy DF1001 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohorts of DF1001 in sequential ascending order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy DF1001 PK/PD Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy DF1001 Expansion in Urothelial Bladder Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort enrolling up to 40 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy DF1001 Expansion in Metastatic Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort enrolling up to 50 patients with metastatic breast cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy DF1001 Expansion in HER-2 High Expressing Cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented high levels HER-2 expression using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy with DF1001 and nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination dose escalation of DF1001 in combination with a PD-1 checkpoint inhibitor in patients with select solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy with DF1001 and Nab paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination dose escalation of DF1001 in combination with a PD-L1 checkpoint inhibitor in patients with select solid tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DF1001</intervention_name>
    <description>Immunotherapy agent targeting NK cells.</description>
    <arm_group_label>Combination Therapy with DF1001 and Nab paclitaxel</arm_group_label>
    <arm_group_label>Combination Therapy with DF1001 and nivolumab</arm_group_label>
    <arm_group_label>Monotherapy DF1001 Dose Escalation</arm_group_label>
    <arm_group_label>Monotherapy DF1001 Expansion in HER-2 High Expressing Cancers</arm_group_label>
    <arm_group_label>Monotherapy DF1001 Expansion in Metastatic Breast Cancer</arm_group_label>
    <arm_group_label>Monotherapy DF1001 Expansion in Urothelial Bladder Cancer</arm_group_label>
    <arm_group_label>Monotherapy DF1001 PK/PD Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Anti-PD-1 immunotherapy agent</description>
    <arm_group_label>Combination Therapy with DF1001 and nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel</intervention_name>
    <description>A chemotherapy treatment combining paclitaxel with albumin</description>
    <arm_group_label>Combination Therapy with DF1001 and Nab paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: General (applies to all cohorts)&#xD;
&#xD;
          1. Signed written informed consent.&#xD;
&#xD;
          2. Male or female patients aged ≥ 18 years.&#xD;
&#xD;
          3. Histologically or cytologically proven locally advanced or metastatic solid tumors.&#xD;
             Primary tumor must have documented HER2 expression by immunohistochemistry.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry&#xD;
             and an estimated life expectancy of at least 3 months.&#xD;
&#xD;
          5. Baseline Left Ventricular Ejection Fraction (LVEF) ≥ 55% measured by echocardiography&#xD;
             (preferred) or multigated acquisition (MUGA) scan.&#xD;
&#xD;
          6. Adequate hematological function.&#xD;
&#xD;
          7. Adequate hepatic function.&#xD;
&#xD;
          8. Adequate renal function.&#xD;
&#xD;
          9. Effective contraception for women of child bearing potential (WOCBP) patients as&#xD;
             defined by World Health Organization (WHO) guidelines for 1 &quot;highly effective&quot; method&#xD;
             or 2 &quot;effective&quot; methods.&#xD;
&#xD;
        Inclusion Criteria: Dose Escalation&#xD;
&#xD;
          1. Evidence of objective disease, but participation does not require a measurable lesion.&#xD;
&#xD;
          2. Archived tumor biopsy available.&#xD;
&#xD;
        Inclusion Criteria: &quot;3+3&quot; Nivolumab Combination Cohort&#xD;
&#xD;
          1. Eligible to receive nivolumab per its label for a malignancy of epithelial origin; or&#xD;
&#xD;
          2. Have no standard therapy available, or standard therapy has failed, and must not have&#xD;
             received nivolumab prior to joining the study.&#xD;
&#xD;
        Inclusion Criteria: &quot;3+3&quot; Nab paclitaxel Combination Cohort&#xD;
&#xD;
          1. Eligible for treatment with nab paclitaxel. In this case, additional inclusion&#xD;
             criteria include also no exposure to taxanes in the last 6 months; or&#xD;
&#xD;
          2. Have tumor for which no standard therapy exists, or tumor for which standard therapy&#xD;
             has failed. In this case, patients should also not have been treated with a taxane&#xD;
             over the last 6 months.&#xD;
&#xD;
        Inclusion Criteria: Safety/PK/PD Expansion Cohorts&#xD;
&#xD;
          1. Fresh tumor biopsy must be obtained during the screening window.&#xD;
&#xD;
          2. HER2 by immunohistochemistry (IHC).&#xD;
&#xD;
          3. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST&#xD;
             1.1.&#xD;
&#xD;
        Inclusion Criteria: Urothelial Bladder Cancer Expansion Cohort&#xD;
&#xD;
          1. Histologically or cytologically documented locally advanced or metastatic transitional&#xD;
             cell carcinoma of the urothelium (including renal pelvis, ureters, urinary urothelial,&#xD;
             urethra).&#xD;
&#xD;
          2. Patients must have radiographic disease progression after their last line of therapy.&#xD;
&#xD;
          3. Patients must have received one (and no more than one) platinum-containing regimen&#xD;
             (eg, platinum plus another agent such as gemcitabine, methotrexate, vinblastine,&#xD;
             doxorubicin, etc.) for inoperable locally advanced or metastatic urothelial carcinoma&#xD;
             with radiographic progression or with recurrent disease.&#xD;
&#xD;
          4. Patients must have received treatment with a checkpoint inhibitor (CPI) (i.e.,&#xD;
             anti-PD-1 or anti-PD-L1), with radiographic progression.&#xD;
&#xD;
          5. Patients must have expression of HER2 by IHC.&#xD;
&#xD;
          6. A fresh tumor biopsy must be obtained during the screening window.&#xD;
&#xD;
          7. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST&#xD;
             1.1.&#xD;
&#xD;
        Inclusion Criteria: Metastatic Breast Cancer (MBC) Expansion Cohort&#xD;
&#xD;
          1. Patients must have histologically confirmed MBC.&#xD;
&#xD;
          2. Patients must have received no more than 3 prior lines of cytotoxic therapy for&#xD;
             metastatic disease.&#xD;
&#xD;
          3. Patients must have received a taxane and an anthracycline unless anthracycline is&#xD;
             contraindicated.&#xD;
&#xD;
          4. Patients must have HER2 expression by IHC.&#xD;
&#xD;
          5. Patients must have progressed (radiographically) after their last line of systemic&#xD;
             therapy.&#xD;
&#xD;
          6. A fresh tumor biopsy must be obtained during the screening window.&#xD;
&#xD;
        Inclusion Criteria: HER-2 High Basket Cohort&#xD;
&#xD;
          1. Patients with any solid tumor except breast cancer or gastric cancer HER2 high&#xD;
             expression by IHC.&#xD;
&#xD;
          2. Patients must have received at least one prior line of an approved or established&#xD;
             therapy.&#xD;
&#xD;
          3. A fresh tumor biopsy must be ob tained during the screening window.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent treatment with a non-permitted drug as in Non-Permitted Medicines and&#xD;
             Therapies section. Previous treatment with drugs that specifically target the HER2&#xD;
             pathway (mAb or tyrosine kinase inhibitor [TKI]) is acceptable providing washout&#xD;
             period (4 weeks for mAbs or protein therapeutics and 2 weeks for a TKI).&#xD;
&#xD;
          2. Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy [with the&#xD;
             exception of palliative bone directed radiotherapy], immune therapy, or cytokine&#xD;
             therapy except for erythropoietin), major surgery (excluding prior diagnostic biopsy),&#xD;
             concurrent systemic therapy with steroids or other immunosuppressive agents, or use of&#xD;
             any investigational drug within 28 days before the start of study treatment.&#xD;
             Short-term administration of systemic steroids (i.e., for allergic reactions or the&#xD;
             management of immune-related adverse events [irAEs]) is allowed.&#xD;
&#xD;
             Note: Patients receiving bisphosphonates are eligible provided treatment was initiated&#xD;
             at least 14 days before the first dose of DF1001.&#xD;
&#xD;
          3. Previous malignant disease other than the target malignancy to be investigated in this&#xD;
             study within the last 3 years, with the exception of basal or squamous cell carcinoma&#xD;
             of the skin or cervical carcinoma in situ.&#xD;
&#xD;
          4. Rapidly progressive disease.&#xD;
&#xD;
          5. Active or history of central nervous system (CNS) metastases.&#xD;
&#xD;
          6. Receipt of any organ transplantation including autologous or allogeneic stem-cell&#xD;
             transplantation.&#xD;
&#xD;
          7. Significant acute or chronic infections (including historic positive test for human&#xD;
             immunodeficiency virus [HIV], or active or latent hepatitis B or active hepatitis C&#xD;
             tested during the screening window).&#xD;
&#xD;
          8. Preexisting autoimmune disease (except for patients with vitiligo) needing treatment&#xD;
             with systemic immunosuppressive agents for more than 28 days within the last 3 years&#xD;
             or clinically relevant immunodeficiencies (eg, dys-gammaglobulinemia or congenital&#xD;
             immunodeficiencies), or fever within 7 days of Day 1.&#xD;
&#xD;
          9. Known severe hypersensitivity reactions to mAbs (≥ Grade 3 NCI-CTCAE v5.0), any&#xD;
             history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partly&#xD;
             controlled asthma).&#xD;
&#xD;
         10. Persisting toxicity related to prior therapy &gt; Grade 1 NCI-CTCAE v5.0, however&#xD;
             alopecia and sensory neuropathy ≤ Grade 2 is acceptable.&#xD;
&#xD;
         11. Pregnancy or lactation in females during the study.&#xD;
&#xD;
         12. Known alcohol or drug abuse.&#xD;
&#xD;
         13. Serious cardiac illness&#xD;
&#xD;
         14. NYHA III of IV heart failure or systolic dysfunction (LVEF &lt; 55%)&#xD;
&#xD;
         15. High-risk uncontrolled arrhythmias ie, tachycardia with a heart rate &gt; 100/min at rest&#xD;
&#xD;
         16. Significant ventricular arrhythmia (ventricular tachycardia) or higher-grade&#xD;
             Atrioventricular block (AV-block; second-degree AV-block Type 2 [Mobitz 2] or&#xD;
             third-degree AV-block)&#xD;
&#xD;
         17. Angina pectoris requiring anti-anginal medication&#xD;
&#xD;
         18. Clinically significant valvular heart disease&#xD;
&#xD;
         19. Evidence of transmural infarction on ECG&#xD;
&#xD;
         20. Poorly controlled hypertension (defined by: systolic &gt; 180 mm Hg or diastolic &gt; 100 mm&#xD;
             Hg)&#xD;
&#xD;
         21. Clinically relevant uncontrolled cardiac risk factors, clinically relevant pulmonary&#xD;
             disease or any clinically relevant medical condition in the opinion of the&#xD;
             Investigator that may limit participation in this study.&#xD;
&#xD;
         22. Severe dyspnea at rest due to complications of advanced malignancy or requiring&#xD;
             supplementary oxygen therapy.&#xD;
&#xD;
         23. All other significant diseases (e.g., inflammatory bowel disease), which, in the&#xD;
             opinion of the Investigator, might impair the patient's ability to participate&#xD;
&#xD;
         24. Any psychiatric condition that would prohibit the understanding or rendering of&#xD;
             informed consent.&#xD;
&#xD;
         25. Legal incapacity or limited legal capacity.&#xD;
&#xD;
         26. Incapable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sean Rossi</last_name>
    <phone>671-588-0086</phone>
    <phone_ext>7060</phone_ext>
    <email>Sean.Rossi@Dragonflytx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Valerin, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony El-Khoueiry, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sharp Healthcare</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Redfern, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anwaar Saaed, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustin Garcia, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Lam, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulka Vaishampayan, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirish Gadgeel, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Goel, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Galsky, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora Bruno, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lainie Martin, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Safran, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Berlin, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Subbiah, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Forget, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Schroder, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Domaine Universitaire du Sart Tilman; CHU de Liege</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Jerusalem, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev og Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes W Pedersen, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Ravaud, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Penel, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillippe Cassier, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecile Vicier, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO - Site Rene Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Campone, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse Cedex 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos-Alberto Gomez-Roca, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariette Labots, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stichting Beoordeling Ethiek Biomedisch Onderzoek</name>
      <address>
        <city>Assen</city>
        <zip>9401 HK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik Verheul, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde Jalving, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maasticht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loes Latten-Jansen, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 ZH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredericus Eskens, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eelke Gort, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER-2</keyword>
  <keyword>NK Cell</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Urothelial Bladder Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

